Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera’s Board of Directors Reaffirms Support of Merger with Pfizer

Revised transaction values Metsera at up to $86.25 per share Metsera’s Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer Transaction creates real, certain and immediate value…